August 29th 2025
Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Study Finds Distinct Tumor Microenvironment Characteristics in HBV-Related HCC
February 28th 2024The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.
Read More
Patients With Early vs Advanced HCC Show Distinct Gut Microbiota Alterations
February 21st 2024Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.
Read More
Nutritional Intervention May Improve Outcomes but Is Underresearched in Ovarian Cancer
February 14th 2024A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.
Read More
CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds
February 2nd 2024In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.
Read More
Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era
January 5th 2024An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
Read More
ICYMI: Highlights From EHA 2023
December 26th 2023The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.
Read More
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Is Genome Editing the Next Step in Immunotherapy Innovation? Experts Think So
December 11th 2023Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says
November 22nd 2023A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
ASN Kidney Week Returns to Philadelphia to Highlight Latest Innovations, Issues in Renal Care
October 30th 2023The American Society of Nephrology (ASN) Kidney Week 2023 will take place in Philadelphia, Pennsylvania, from November 2-5, as experts from across the globe gather to discuss the latest innovations in renal care and current issues facing the field.
Read More